Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an 'Outperform' rating on Anika Therapeutics (NASDAQ:ANIK) and raised the price target from $24 to $28.
November 03, 2023 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anika Therapeutics' price target has been raised from $24 to $28 by Barrington Research, which maintains an 'Outperform' rating on the stock.
The raised price target and maintained 'Outperform' rating by Barrington Research indicates a positive outlook for Anika Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100